Skip to main content
OpenTrials
Completed

NCT Number: NCT02379572

Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas

Standard treatment of glioblastomas (GBMs) consists of microsurgical resection followed by concomitant chemoradiation. The extent of resection is one of the most important prognostic factors with significant influence on the survival of patients. State of the art technique to achieve the most radical resection possible in conventional surgery is fluorescence-guidance with 5-aminolevulinic acid (5-ALA). If available, intraoperative MRI (iMRI)-guided tumor resection enables an intraoperative resection control and subsequent continuation of surgery if contrast enhancing tumor remnants are found. Therefore a more radical resection and longer survival of patients might be possible. To date no comparison of these two leading technologies for GBM-surgery is available to identify the best surgical therapy of this fatal disease and to justify significant healthcare-economic differences between both technologies.

Goal of this study is to assess the value of iMRI guidance in the resection of GBMs in comparison to conventional 5-ALA microsurgery. Primary endpoint is the number of total resections (no residual contrast enhancement) in the postoperative MRI (T1+CM within 48 hours after surgery) in each group. Secondary endpoints are perioperative clinical data, progression free survival, patients' clinical condition and overall survival.

The study design was chosen to be a parallel-group approach to compare iMRI and 5-ALA centers (n=13) to exclude possible bias which might be found by randomizing patients within individual iMRI centers and to have surgeons with the most experience possible in use of each respective technology.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Neurosurgery, Universitätsklinikum Bonn, Bonn, Germany, Bonn, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • In MRI suspected primary singular untreated GBM
  • Planned total resection of the tumor according to the surgeon
  • Patient ≥18 years, ≤80 years
  • Preoperative KPS ≥ 60%, American Society of Anesthesiologists (ASA) score 1 and 2
  • Patients' informed consent

Exclusion criteria

  • Tumors of the midline, basal ganglia, cerebellum, brain stem, eloquent areas
  • Multifocal glioblastoma
  • Substantial (>50%), non-contrast enhancing tumor areas suggesting low-grade glioma with malignant transformation
  • Contraindications to MRI
  • Inability to give consent because of language barrier or dysphasia
  • Histological diagnosis other than Glioblastoma multiforme WHO °IV
  • Increased risk of thrombosis (e.g. Factor V Leiden)
  • Pregnancy or breast feeding
  • Hypersensibility for 5-ALA oder porphyrins
  • Acute or chronic Porphyria
  • Renal insufficiency
  • Hepatic insufficiency
  • High likelihood of inability to receive adjuvant therapy

Treatment and study plan

iMRI-guided surgery

Device

For iMRI-guided glioma resections the surgery can be paused and a direct intraoperative resection control is possible by performing an intraoperative MRI scan. If residual tumor is found, the resection might be continued.

5-ALA-guided surgery

Drug

For 5-ALA guided glioma resections patients have to drink 100ml of a solution with 5-Aminolevulinic acid 4-6 hours before surgery. Intraoperatively the light source of the surgical microscope can be switched to a certain wave length to enable fluorescence of the glioma cells, which helps resecting the tumor as radical as possible.

Primary outcomes

  1. Complete resections in the postoperative MRI (T1+/-CM) within 48 hours after surgery

    Time frame: 48 hour

    Completeness of resection in the postoperative MRI within 48h after surgery. Blinded analysis by an independent radiologist.

Secondary outcomes

  1. Patients' clinical condition (KPS)

    Time frame: preoperative (day before surgery), 1 week, 3Months, 6Months, 9Months, 12Months after surgery

    -KPS clinical scoring

  2. Patients' clinical condition (NIHSS)

    Time frame: preoperative (day before surgery), 1 week, 3Months, 6Months, 9Months, 12Months after surgery

    -NIHSS stroke score

  3. Patients' clinical condition (QoL)

    Time frame: preoperative (day before surgery), 1 week, 3Months, 6Months, 9Months, 12Months after surgery

    -quality of life (EORTC) questionnaire

  4. ICU and hospital stay after surgery

    Time frame: Time of hospital stay (average 7days)

    -ICU and overall hospital stay after surgery

  5. Patients' adjuvant treatment

    Time frame: 3Months, 6Months, 9Months, 12Months after surgery

    -adjuvant treatment each patient has received

  6. Recurrent tumor growth (RANO criteria)

    Time frame: 3Months, 6Months, 9Months, 12Months after surgery

    -recurrent tumor growth (RANO criteria) according to local tumor boards and independent blinded analysis

  7. Follow-up imaging

    Time frame: 3Months, 6Months, 9Months, 12Months after surgery

    -follow-up imaging 3, 6, 9, 12 months postoperative incl. independent blinded analysis

  8. Histology

    Time frame: 1 week after surgery

    Histological analysis

  9. MGMT (O6-methylguanine-DNA-methyltransferase) analysis

    Time frame: 1 week after surgery

    MGMT promoter analysis (Routine molecular diagnostics)

  10. IDH-1 (isocitrate dehydrogenase) analysis

    Time frame: 1 week after surgery

    IDH-1 mutation analysis (Routine molecular diagnostics)

  11. Progression-free survival (PFS)

    Time frame: Day of surgery - 6 months - 12 months

    6M&12M-PFS

  12. Overall survival (OS)

    Time frame: Day of surgery - Death of patient (Max. 10 years follow-up)

    OS of patients

Other outcomes

  1. Preoperative tumor localization and resectability concerning eloquent regions

    Time frame: Blinded analysis of preoperative imaging (not older than 3 days prior to surgery)

    Independent blinded analysis of the preoperative imaging data by a blinded neurosurgeon with extensive experience in the resection of gliomas. Analysis will be done before the final evaluation of results. (Within 12 months)

Sponsors and collaborators

Lead sponsor

University Hospital Tuebingen

Other

Registry information

Official study title

Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas - A Prospective Multicenter Parallel Group Clinical Trial

Important dates

Study start
2015
Primary completion
2020
Study completion
2021
First posted
Mar 5, 2015
Registry last updated
Oct 22, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.